By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roched has entered into an agreement with ChanTest to evaluate the safety of potential drug compounds.

Under the terms of the deal announced today, ChanTest, an ion channel screening provider, will use Roche's xCelligence System RTCA Cardio Instrument and Cellular Dynamics International's iCell Cardiomyocytes to evaluate pharmacological responses to a number of compounds that have been selected based on their known effects on ion channels.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.